Related references
Note: Only part of the references are listed.Bactericidal Activity and Mechanism of Action of AZD5847, a Novel Oxazolidinone for Treatment of Tuberculosis
V. Balasubramanian et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis
Vija Skripconoka et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
PA-824, moxifloxacin and pyrazinamide combination therapy for tuberculosis
Rodney Dawson et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
TMC207 becomes bedaquiline, a new anti-TB drug
Juan Carlos Palomino et al.
FUTURE MICROBIOLOGY (2013)
Advances in the development of new tuberculosis drugs and treatment regimens
Alimuddin Zumla et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Randomized Clinical Trial of Thrice-Weekly 4-Month Moxifloxacin or Gatifloxacin Containing Regimens in the Treatment of New Sputum Positive Pulmonary Tuberculosis Patients
Mohideen S. Jawahar et al.
PLOS ONE (2013)
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action
Katherine A. Sacksteder et al.
FUTURE MICROBIOLOGY (2012)
Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide
Robert S. Wallis et al.
PLOS ONE (2012)
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis
A Krüüner et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2006)
Share Paper
